astragaluslongevityimmune functiontelomerasecycloastragenolTA-65adaptogensnatural health

Astragalus: Longevity, Immune Function, and Telomerase Research

8 February 2026 · 17 min read

Astragalus: Longevity, Immune Function, and Telomerase Research

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice and should not be used to diagnose, treat, cure, or prevent any health condition. Always consult a qualified healthcare professional before making changes to your supplement regimen, particularly if you are taking prescribed medications, are immunocompromised, have an autoimmune condition, or have a diagnosed health condition.

Astragalus membranaceus — known as Huang Qi (yellow energy) in traditional Chinese medicine — has been used as a primary tonic herb for more than two millennia. It appears in the Shennong Bencao Jing, the foundational Chinese pharmacopoeia, classified as a superior-grade herb suited to prolonged daily use for vitality, immune support, and longevity. Today, it is one of the most commercially widespread adaptogenic herbs globally and, crucially, one of the most studied — particularly for immune modulation and, more recently, for a remarkable line of research into telomere biology.

This article examines the evidence across three areas where astragalus has attracted serious scientific interest: immune system modulation, telomerase activation and longevity biology, and adaptogenic and cardiovascular effects. The research picture is genuinely interesting — but it requires careful calibration between what animal and laboratory data show and what has been confirmed in human clinical trials.

Taxonomy and Naming Conventions

Astragalus membranaceus (Fisch.) Bge. belongs to the Fabaceae family — the legume family — and is one of approximately 2,000 species within the genus Astragalus, making it one of the largest genera of flowering plants. The genus spans temperate zones of the northern hemisphere, and many species are entirely unstudied and have no traditional medicinal use.

A naming convention that frequently causes confusion: Astragalus membranaceus and Astragalus mongholicus are the same species — or more precisely, A. mongholicus (Bge.) is now treated as synonymous with A. membranaceus var. mongholicus in most current botanical classifications. Both names appear widely in the research literature; the key point is that they refer to the same plant with regional naming variants, and both are the source of commercially available Huang Qi. When evaluating research, either name can be treated as equivalent for most practical purposes. The species used in traditional Chinese medicine and the vast majority of pharmacological studies is this single plant — not the broader genus — and this distinction matters because astragalus supplements derived from different species (including several North American Astragalus species) are pharmacologically unrelated.

Primary Active Constituents

Astragalus membranaceus has a complex phytochemical profile. The bioactive fraction can be grouped into four main compound classes:

Astragalosides (I–IV) are triterpene saponins and represent the principal marker compounds used to identify and standardise astragalus extracts. Astragaloside IV is the most extensively studied of the group and has attracted particular attention for its cardiovascular and telomere-related effects. These saponins are unique to the Astragalus genus and serve as the primary quality marker in standardised commercial preparations.

Cycloastragenol is a triterpenoid aglycone derived from astragaloside IV through hydrolysis — essentially the sugar-free core molecule. It is present in the root in small quantities naturally but can also be produced by chemical hydrolysis of astragaloside IV. Cycloastragenol has become the central compound in telomerase research and is the active ingredient in the commercial preparation TA-65, discussed in detail below.

Astragalus polysaccharides (APS) are high-molecular-weight carbohydrate polymers that have been the focus of the majority of astragalus immune research. APS are structurally distinct from the triterpene fraction and are the primary immune-modulating component, activating pattern recognition receptors on innate immune cells via mechanisms similar to beta-glucans from functional mushrooms. The polysaccharide fraction is water-soluble and well-extracted in traditional decoctions.

Flavonoids — primarily calycosin and formononetin — are isoflavone compounds with oestrogenic and antioxidant activity. These compounds contribute to astragalus's antioxidant effects and may play a role in its reported cardiovascular activity. Formononetin is also found in red clover (Trifolium pratense), where it is one of the primary phytoestrogenic compounds. Calycosin is more specific to Astragalus and has been investigated for cardiovascular endothelial effects in preclinical research.

Immune Research: What the Evidence Shows

The immune applications of astragalus are among its most thoroughly investigated properties, with a body of research spanning cell culture studies, animal models, and human clinical trials.

APS and Innate Immune Activation

Astragalus polysaccharides activate innate immune cells through toll-like receptor (TLR) signalling — particularly TLR-4 — and through direct stimulation of macrophage pattern recognition pathways. The documented downstream effects include:

Macrophage activation: APS stimulates macrophage phagocytic capacity, enhances production of reactive oxygen species (ROS) for pathogen destruction, and upregulates pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) within macrophages at concentrations encountered in supplementation. This is the same immune activating pattern seen with functional mushroom beta-glucans — a stimulation of the innate arm of immune defence without direct antigen-specific action.
NK cell activity: Natural killer cells — innate immune cells that target virally infected and abnormal cells — show increased cytotoxic activity following APS administration in both animal and human studies.
T-cell proliferation: APS has consistently promoted T-lymphocyte proliferation in stimulated cell culture assays, and several human trials have observed increased CD4+ T-cell counts and improved CD4+/CD8+ ratios following astragalus supplementation, particularly in immunocompromised populations.

Systematic Review Evidence

A 2020 systematic review by Tin Moe Moe Aung and colleagues examined the clinical evidence for astragalus immune effects across available human trials. The review found directionally consistent evidence of immune marker improvement — including NK cell activity, T-cell subsets, and immunoglobulin levels — particularly in populations with baseline immune dysfunction. The reviewers noted that trial heterogeneity, small sample sizes, and variable extract standardisation across studies limited the strength of pooled conclusions, and called for larger, better-controlled RCTs. This pattern is familiar across the adaptogen literature: mechanistically plausible effects in cell and animal studies, consistent directional findings in human trials, but trial quality insufficient for definitive clinical recommendations.

Adjuvant Use in Cancer Treatment

Traditional Chinese medicine has incorporated Huang Qi as an adjuvant in cancer treatment protocols for centuries, and this application has attracted meaningful modern research. The immunostimulatory effect of APS has been the primary rationale for its use alongside conventional chemotherapy and radiotherapy — contexts where treatment-induced immunosuppression creates significant clinical vulnerability.

Several small Chinese RCTs have examined astragalus-based preparations as adjuncts during chemotherapy for non-small cell lung cancer, gastric cancer, and colorectal cancer, with results showing improved immune marker profiles (T-cell counts, NK activity), reduced severity of treatment-related adverse effects, and in some analyses, improved disease-free survival. These findings should be interpreted cautiously: many studies are published in Chinese-language journals with varying methodological rigour, populations are heterogeneous, and the preparations used are often complex multi-herb formulae rather than isolated astragalus extracts, making attribution to a single herb difficult. The evidence is hypothesis-generating and promising — it is not sufficient to support clinical recommendation, but it justifies continued rigorous investigation.

Telomere Biology and the Cycloastragenol Connection

The most scientifically distinctive angle of astragalus research — and the one that has attracted the most mainstream longevity interest — concerns its relationship with telomere biology via cycloastragenol.

Telomere Biology: A Brief Primer

Telomeres are protective DNA-protein caps at the ends of chromosomes, analogous to the plastic tips on shoelaces. With each cell division, telomeres shorten incrementally. When telomeres reach a critically short length, cells enter a state of senescence (permanent growth arrest) or apoptosis. Telomere shortening is a primary molecular marker of cellular ageing, and accelerated telomere attrition is associated with age-related diseases including cardiovascular disease, immune dysfunction, and cognitive decline. Telomerase — the enzyme that can rebuild telomere length — is highly active in stem cells and germline cells but largely suppressed in most somatic (body) cells, allowing progressive shortening over a lifetime. Activating or preserving telomerase activity in targeted immune cell populations is one of the central aims of the longevity biology field.

Cycloastragenol and TA-65

Cycloastragenol — the aglycone of astragaloside IV — is the compound that generated the first commercially significant telomerase activation claim. TA-65, a proprietary preparation of cycloastragenol developed by Geron Corporation and subsequently licensed to T.A. Sciences, became the subject of a notable series of studies in the early 2010s.

Harley et al. (2011), published in Rejuvenation Research, examined the effects of TA-65 supplementation in a cohort of healthy middle-aged adults over one year. The study found that TA-65 supplementation was associated with a statistically significant reduction in the percentage of short telomeres in peripheral blood mononuclear cells — immune cells including T-lymphocytes and NK cells. Importantly, mean telomere length across all cells did not increase; rather, the proportion of critically short telomeres decreased, suggesting that TA-65 may preferentially allow telomerase activity in the cells most in need of telomere extension. The study also observed improvements in immune cell profiles, including reduced senescent CD8+CD28- T-cells. This was a landmark finding in the field — the first controlled human evidence that a small molecule activator of telomerase could measurably alter telomere length distribution in immune cells.

de Jesus et al. (2012), examining telomerase activation in lymphocytes, provided complementary cell-level evidence that cycloastragenol can upregulate telomerase activity (measured by TERT expression and TRAP assay) in activated human T-cells and NK cells, at concentrations relevant to supplementation. This mechanistic confirmation strengthened the biological plausibility of the Harley clinical findings.

Important Calibration Points

Several caveats are essential when interpreting this research:

The Harley 2011 study lacked a randomised placebo control — participants selected their dose tier, creating selection bias risk, and there was no blinded comparison group. The findings are hypothesis-supporting, not hypothesis-confirming at a clinical evidence level.

Telomere length improvement in immune cells does not straightforwardly translate to longevity extension or disease prevention in humans. The relationship between telomere dynamics in peripheral blood cells and overall lifespan is complex, bidirectional, and not yet mechanistically resolved. Observational data shows that shorter telomeres are associated with greater disease risk — but whether actively lengthening short telomeres in blood cells reduces that risk has not been established in randomised controlled trials in humans.

There is also a theoretical concern around indiscriminate telomerase activation: since telomerase activity is suppressed in most somatic cells partly as a cancer-suppression mechanism (cancerous cells frequently reactivate telomerase to achieve unlimited replication), interventions that activate telomerase broadly raise questions about oncogenic risk. Available evidence from animal studies using cycloastragenol has not found increased cancer incidence at supplementation doses, but long-term human safety data is limited. This is not a reason to dismiss the research — it is a reason to monitor the literature, dose conservatively, and avoid framing cycloastragenol as a proven longevity intervention.

The honest scientific summary: the telomerase research on cycloastragenol is among the most intriguing in botanical science, the mechanism is real and measurable, and the early human data is promising — but this remains an active research frontier, not an established clinical intervention for longevity extension in humans.

Adaptogenic Effects: HPA Axis and Fatigue

Astragalus is classified as an adaptogen — a herb that non-specifically supports the body's capacity to handle and recover from physiological and psychological stress. This classification carries mechanistic support: animal research has demonstrated that APS supplementation can moderate hypothalamic-pituitary-adrenal (HPA) axis hyperactivation under acute and chronic stress conditions, reducing peak corticosterone elevations and attenuating the immune suppression that typically follows sustained stress exposure.

Human evidence for fatigue reduction is less comprehensively studied in astragalus compared to some other adaptogens. Within the broader adaptogen category, ashwagandha has the most robust cortisol-lowering RCT evidence, rhodiola rosea has the strongest data for mental and physical fatigue under acute stress, and eleuthero (Eleutherococcus senticosus) has historical data from Soviet sports medicine research. Astragalus sits alongside these within the adaptogen class, with plausible HPA mechanisms and some clinical evidence of improved wellbeing and reduced fatigue in chronically ill or immunocompromised populations — but fewer well-powered RCTs specifically targeting fatigue outcomes in healthy adults. For a structured comparison of adaptogens by evidence category, see our article on the adaptogenic herb comparison framework.

Cardiovascular Research

Astragaloside IV has attracted specific research attention for cardiovascular effects, driven by findings from cell culture and animal models.

The primary proposed mechanism involves endothelial function. Astragaloside IV appears to promote nitric oxide (NO) synthesis in vascular endothelial cells — the thin inner lining of blood vessels. Nitric oxide is a potent vasodilator and plays a central role in maintaining vascular tone, reducing platelet aggregation, and protecting endothelial integrity against oxidative stress. In animal models of myocardial ischaemia (heart tissue oxygen deprivation), astragaloside IV administration has been associated with reduced infarct size, improved cardiac function indices, and preservation of endothelial architecture — findings that have generated interest in its cardioprotective potential.

The flavonoid fraction — particularly calycosin and formononetin — has been separately investigated for antioxidant protection of vascular tissue and mild anti-inflammatory effects in endothelial cell models.

The qualification here is important: the cardiovascular evidence for astragalus is predominantly from animal studies and mechanistic cell culture research. Well-designed human RCTs examining cardiovascular outcomes are limited. The biological mechanisms are coherent and testable, but whether they translate to clinically meaningful cardiovascular benefits in human patients has not been established. Promising preclinical cardiovascular findings frequently fail to replicate at clinical scale — this caveat applies to astragalus's cardiovascular data as it does to most botanical cardiovascular claims.

Safety Profile and Drug Interactions

Astragalus membranaceus has a long traditional use history and a generally favourable safety profile in reported clinical research.

Immunostimulant caution in autoimmune conditions. The immune-activating properties of APS are the same properties that raise concern in people with autoimmune disease — conditions characterised by an immune system already overactivated against self-tissue. Individuals with rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, or other autoimmune conditions should seek specialist advice before using astragalus. Upregulating immune activity in these contexts could theoretically exacerbate disease activity.

Immunosuppressant interactions. APS's immune-stimulating effects may reduce the effectiveness of immunosuppressant medications used in transplant patients (cyclosporin, tacrolimus, mycophenolate) or in managing autoimmune disease. This is mechanistically plausible and clinically relevant — patients on these medications should not add astragalus without explicit guidance from their prescriber.

Anticoagulants. Some in vitro evidence suggests mild anti-platelet activity from astragalus constituents, raising a theoretical additive bleeding risk alongside warfarin, apixaban, or antiplatelet drugs. The clinical magnitude of this interaction is not well characterised.

General tolerability. In adults without autoimmune disease or immunosuppressant therapy, astragalus is generally well-tolerated. Gastrointestinal side effects are uncommon and mild when reported. No significant hepatotoxicity signal has emerged in the clinical literature — contrasting with some other botanicals such as gotu kola, where hepatotoxic case reports have appeared.

Dosing Considerations

Clinical trials and traditional practice have used a wide range of astragalus preparations:

Standardised extract capsules: Most modern research has used concentrated extracts standardised to astragaloside content. A dose of 250–500mg per day of a standardised extract (typically standardised to 0.5–2% astragalosides) is within the range used in clinical studies and is a reasonable starting point for general immune support.
Traditional decoctions: Traditional Chinese medicine protocols use 9–30g of dried root per day, simmered as a decoction (the thick root slices, Huang Qi, are visually distinctive and widely available in Chinese herbal medicine practice). The decoction form is well-suited to polysaccharide extraction, as APS are water-soluble.
Cycloastragenol / TA-65: Research doses in the Harley 2011 study ranged from 5mg to 25mg of cycloastragenol per day. TA-65 as a commercial product is considerably more expensive than standard astragalus extracts, reflecting the concentration process required to isolate cycloastragenol from the root matrix.
Duration: Immune studies showing measurable effects have typically used 4–12 week supplementation periods. The telomere data examined 12-month supplementation.

For those comparing the longevity-oriented botanical options available, reishi mushroom immune and longevity research provides a useful parallel evidence review across a different compound class with complementary mechanisms.

How Astragalus Fits in the Broader Adaptogen Landscape

Astragalus occupies a distinct position within the adaptogen category — one that is shaped by the unusual breadth of its research literature and the particular depth of its immune and telomere data.

Where ashwagandha leads on cortisol-lowering evidence and rhodiola leads on acute fatigue performance, astragalus leads on polysaccharide-mediated immune stimulation depth and the uniquely specific telomere biology research — a line of research that no other adaptogen has generated in comparable detail. Its closest functional overlap is with reishi mushroom (shared immune modulation via polysaccharide mechanisms and shared longevity-associated traditional use), but the compounds and specific mechanisms are distinct: reishi's immune effects are primarily beta-glucan driven via Dectin-1 receptors, while astragalus's APS activity is predominantly TLR-4 mediated. The two compounds are complementary rather than redundant.

The combination of immune modulation, HPA adaptogenic activity, cardiovascular endothelial research, and the cycloastragenol-telomerase story gives astragalus a genuinely multifaceted evidence profile. The breadth of this profile is both its strength and its complexity — the different compound classes (APS, astragalosides, cycloastragenol, flavonoids) act through different mechanisms and are not interchangeable. A preparation well-standardised for polysaccharides is not necessarily delivering meaningful cycloastragenol content, and vice versa. Understanding which outcome you are targeting determines which preparation is most relevant.

Those interested in how collagen-synthesis and connective tissue longevity angles compare with astragalus's telomere research can find useful comparative detail in our article on gotu kola's collagen and cognitive evidence, which explores how botanical anti-ageing claims can be evaluated across different molecular targets.

For practitioners and researchers tracking the evolving compound-level evidence across botanical longevity research, the RetaLABS research resource aggregates emerging findings across these areas.

Summary

Astragalus membranaceus (Huang Qi) presents one of the most pharmacologically layered profiles in the adaptogen category. Its active constituents — astragalosides I–IV, cycloastragenol, astragalus polysaccharides, calycosin, and formononetin — operate through distinct mechanisms across immune, cardiovascular, and cellular longevity pathways.

The immune evidence is the most clinically established: APS activates macrophages, NK cells, and T-cell populations through TLR-4 and related pathways, with directionally consistent human trial data across immune marker outcomes in immunocompromised and ill populations, supported by the 2020 Tin Moe Moe Aung systematic review. The adjuvant oncology evidence is promising but methodologically limited.

The telomerase research is the most scientifically distinctive finding: Harley et al. (2011) and de Jesus et al. (2012) established that cycloastragenol can activate telomerase in immune cells and measurably alter the distribution of short telomeres in peripheral blood — a mechanistically real effect that represents a genuine advance in botanical longevity science. It is not, however, established evidence of longevity extension in humans, and that distinction matters for accurate interpretation.

The adaptogenic and cardiovascular data is mechanistically coherent but supported by less rigorous human evidence — animal and cell culture data predominates, and well-powered human RCTs for fatigue and cardiovascular outcomes remain limited.

For practical use: ensure the preparation is standardised to astragaloside content for the immune application, or specifically to cycloastragenol content if the telomere application is the primary interest. Avoid in active autoimmune disease or on immunosuppressant therapy without specialist guidance. Dose at 250–500mg per day of standardised extract, or 9–30g dried root in traditional decoction form, for general immune support and adaptogenic use.

This article is for informational and educational purposes only. It does not constitute medical advice and should not be used to diagnose, treat, cure, or prevent any health condition. If you have an autoimmune condition, are taking immunosuppressant medications, or are undergoing active treatment for a medical condition, consult your healthcare provider before using astragalus or any supplement containing cycloastragenol.